Novasep Holding SAS

If deal activity, capital investment and quantity of active clinical trials are any indication, the gene therapy sector will continue its growth spurt in 2021. At the end of the third quarter of 2020,

Regenerative medicines have made significant advancements in patient care, especially for rare diseases and small patient populations who no longer have to fear being told there are no other options.

Medical device companies are increasingly looking at digital health and diagnostics solutions to bolster their portfolios. This week, Thermo Fisher Scientific announced plans to acquire molecular di

UCB S.A. ’s ambitions to be a key player in gene therapy have advanced with the acquisition of fellow Belgian firm Handl Therapeutics and an R&D collaboration with Lacerta Therapeutics Inc of the